(Figure 5C) This recapitulates the outcome of genetic FADS1 and FADS2 inhibition in MOLM-13 AML cells and suggests that FADS1 and/or FADS2 may offer a novel pharmacologic target for AML. The gene discussed is FADS2; the disease is acute myeloid leukemia.